Introduction
============

Hypoxia and acidosis are common phenomena in tumors, and adaptations to these micro environments are crucial for tumor growth and invasiveness [@B1]. Hypoxia-inducible gene products have recently been investigated as candidates for biomarkers and therapeutic targets [@B2], [@B3]. Carbonic anhydrase (CA) XII is a transmembrane zinc metalloenzyme that catalyzes the reversible hydration of carbon dioxide to form bicarbonate, and is involved in acidification of the microenvironment. Several recent studies reported the expression of CA XII in various types of cancers and its important roles in cancer development, tumor invasion, and possibly metastasis [@B4]-[@B11]. However, a consensus has not yet been reached about its prognostic significance in cancer. Previous studies demonstrated that the expression of CA XII correlated with a good prognosis [@B5], [@B7], [@B8], whereas others found that it correlated with a poor prognosis [@B9]-[@B11]. Furthermore, the clinicopathological meaning and prognostic impact of the expression of CA XII has not yet been evaluated in esophageal cancer.

The objectives of the present study were to investigate the clinicopathological significance of the expression of CA XII and determine its relationship with the prognosis of patients with esophageal squamous cell carcinoma (ESCC). Our results revealed the prognostic significance of the expression of CA XII in advanced ESCC.

Materials and Methods
=====================

Patients and primary tissue samples
-----------------------------------

ESCC tumor samples were obtained from 70 patients with histologically proven primary ESCC who underwent esophagectomy (potentially curative R0 resection) at Kyoto Prefectural University of Medicine (Kyoto, Japan) between 1998 and 2009, and were analyzed retrospectively. These samples were embedded in paraffin 24 h after being fixed in formalin. The criteria for patient eligibility included the absence of synchronous tumors or multiple metachronous tumors and not having received preoperative chemotherapy or radiation therapy. We excluded patients with non-curatively resected tumors or non-consecutive data. All patients gave their written informed consent for inclusion in this study. Relevant clinicopathological and survival data were obtained from the hospital database. Staging was principally based on the seventh TNM staging system [@B12].

Immunohistochemistry
--------------------

Paraffin sections (3-μm thick) of tumor tissue were subjected to immunohistochemical staining for CA XII using the avidin-biotin-peroxidase method. Briefly, paraffin sections were dewaxed in xylene and hydrated through a graded series of alcohols. Antigen retrieval was performed by heating the samples in Dako REAL Target Retrieval Solution (Glostrup, Denmark) for 40 min at 95°C. Endogenous peroxidase activity was quenched by incubating the sections for 30 min in 0.3% H~2~O~2~. Sections were incubated for one hour at room temperature with the CA XII antibody (sc-374314; Santa Cruz Biotechnology, Santa Cruz, CA, USA) or hypoxia inducible factor (HIF)-1α antibody (ESEE122; Novus Biologicals, Littleton, CO, USA). The avidin-biotin-peroxidase complex system (Vectastain ABC Elite kit; Vector Laboratories, Burlingame, CA, USA) was used for color development with diaminobenzidine tetrahydrochloride. Sections were counterstained with hematoxylin. These sections were then dehydrated through a graded series of alcohols, cleared in xylene, and mounted. Control sections of known positive ESCC were included in each antibody run, and negative control sections were produced by omitting the primary antibody.

Immunohistochemical samples stained with CA XII were graded semi-quantitatively by considering both the staining intensity and percentage of positive tumor cells using an immunoreactive score (IRS) [@B13]. Staining intensity was scored as 0 (no staining), 1 (weak staining), 2 (moderate staining), or 3 (strong staining). The proportion of positive tumor cells was scored from 0 to 1.0. The score of each sample was calculated as the maximum multiplied product of the intensity and proportion scores (0 to 3.0).

Statistical analysis
--------------------

Statistical analyses were carried out using Fisher\'s exact test to investigate the relationships between clinicopathological parameters and CA XII expression. Survival curves were constructed using the Kaplan-Meier method, and differences in survival were examined using the log-rank test. A multivariate analysis of the factors influencing survival was performed using the Cox proportional hazard model. Differences were considered significant when the associated *p*-value was less than 0.05. All analyses were performed using statistical software (JMP, version 10; SAS Institute Inc., Cary, NC, USA).

Results
=======

CA XII protein expression in human ESCCs
----------------------------------------

An immunohistochemical investigation with the CA XII antibody revealed the expression of CA XII in the parabasal cell layer of normal esophageal mucosa (Fig. [1](#F1){ref-type="fig"}A). We examined the expression of CA XII in 70 primary tumor samples of human ESCC based on their immunohistochemical reactivities. The CA XII protein was mostly expressed in the cell membranes of carcinoma cells (Fig. [1](#F1){ref-type="fig"}B). The CA XII score varied widely between the tumors. The minimum CA XII score was 0, while the maximum was 2.5 (median= 0.40; mean±standard deviation (SD) = 0.65±0.64). Regarding the expression of CA XII in tumors, we divided ESCC patients into 2 groups by referring to the median and mean staining scores; a low grade CA XII expression group with staining scores\<0.5, n=35, and a high grade CA XII expression group with staining scores≥0.5, n=35. Figure [1](#F1){ref-type="fig"}CD shows the representative histopathological findings of low or high CA XII expression samples. Relationships between the expression of CA XII and various clinicopathological parameters were analyzed (Table [I](#TI){ref-type="table"}). A correlation was observed between the expression of CA XII and the pT category (Table [I](#TI){ref-type="table"}). We then analyzed CA XII expression according to the pT category. In patients with pT1 ESCC (n=33), the minimum CA XII score was 0, while the maximum was 2.5 (median= 0.70; mean±SD= 0.80±0.66), and correlations were found between the expression of CA XII and venous invasion (Table [II](#TII){ref-type="table"}). On the other hand, the minimum CA XII score in patients with pT2-3 ESCC (n=37) was 0, while the maximum was 2.4 (median= 0.20; mean±SD= 0.51±0.60), and no correlation was found between the expression of CA XII and any other clinicopathological parameter (Table [III](#TIII){ref-type="table"}). Interestingly, the expression of CA XII was found in precancerous tissue such as severe dysplasia (Fig. [2](#F2){ref-type="fig"}A). These results suggested that CA XII may be induced in esophageal epithelial cells in the early stage of carcinogenesis.

We analyzed the localization of CA XII expression in tumors. In 25 cases, the expression of CA XII was found in the invasive front of the tumor. A correlation was found between the expression of CA XII in the invasive front and the CA XII score (Table [I](#TI){ref-type="table"}). Furthermore, CA XII and HIF-1α protein expression showed a similar pattern, suggesting its primary function contributing to pH homeostasis in microenvironment with hypoxia or acidosis (Fig. [2](#F2){ref-type="fig"}B).

Prognostic impact of CA XII protein expression for patients with ESCC
---------------------------------------------------------------------

We determined the prognostic impact of the expression of CA XII for patients with ESCC. No significant difference was observed in the overall 3-year survival rate between patients with the high grade expression of CA XII and those with the low grade expression of CA XII (Fig. [3](#F3){ref-type="fig"}A). Similarly, no significant differences were observed in the 3-year survival rate between patients with CA XII expression in the invasive front (70.8%) and that of the patients without it (71.5%) (p=0.764). We then analyzed the prognostic significance of the expression of CA XII according to the pT category. In patients with pT1 ESCC, no significant difference was observed in the 3-year survival rate between patients with the high grade expression of CA XII and those with the low grade expression of CA XII (Fig. [3](#F3){ref-type="fig"}B). On the other hand, in patients with pT2-3 ESCC, the 3-year survival rate of patients with the high grade expression of CA XII (29.1 %) was significantly lower than that of patients with the low grade expression of CA XII (70.3 %) (p = 0.011) (Fig. [3](#F3){ref-type="fig"}C).

We then assessed which of the 10 variables examined (age, gender, location of the primary tumor, histological type, tumor size, lymphatic invasion, venous invasion, pN category, pStage, and CA XII expression) influenced survival in patients with pT2-3 ESCC following curative resection of esophageal cancer. A univariate analysis of survival following esophagectomy revealed that lymphatic invasion and CA XII expression were significant prognostic factors (p=0.041 and 0.011, respectively) (Table [IV](#TIV){ref-type="table"}). A multivariate analysis demonstrated that lymphatic invasion, pN category and CA XII expression were independent prognostic factors (p=0.003, 0.007 and 0.001, respectively) (Table [V](#TV){ref-type="table"}). The expression of CA XII was the strongest prognostic factor among all clinicopathological features. These results suggested that the expression of CA XII may be a valuable prognostic factor for patients with advanced ESCC.

Discussion
==========

CA, a class of zinc metalloenzymes that catalyze the reversible hydration of carbon dioxide, participates in various physiological processes by contributing to pH homeostasis [@B4]. Hypoxia is a common phenomenon in tumors, and is associated with malignant behavior, invasiveness, and a poor prognosis [@B1]. Consequently, CA is thought to regulate the microenvironment and contribute to tumor growth and invasiveness. Fifteen active isoforms of CAs, 12 of which are catalytically active, have been identified in mammals to date [@B14]. Of these, CA IX and XII have been examined in various types of tumors and suggested to play a role in oncogenic processes.

In esophageal cancer, several studies demonstrated that the expression of CA IX correlated with a poor prognosis and malignant phenotype in both esophageal adenocarcinoma [@B15] and ESCC [@B16]. Schoppmann et al. showed that the overexpression of CA IX in esophageal cancer was associated with a poorer prognosis and correlated with the expression of HER-2 [@B17], [@B18]. They also showed that the CA IX-expressing tumor stroma was associated with shorter survival in esophageal cancer [@B19]. However, the roles and clinicopathological meaning of the expression of CA XII in esophageal cancer have not yet been evaluated. In the present study, we investigated the expression of CA XII in ESCC and determined its relationships with clinicopathological features and prognosis. To the best of our knowledge, this is the first study to examine the expression of CA XII in human esophageal cancer tissue.

CA XII is a transmembrane and extracellular enzyme that is involved in regulating the acidity of the microenvironment and tumorigenesis [@B2], [@B4]. The overexpression of CAXII was initially detected in renal cell carcinoma, and subsequent studies confirmed its expression in various human neoplasms, such as astrocytoma, glioblastoma, breast, ovarian, cervical, lung, and head and neck cancers [@B4]-[@B11]. Although several studies investigated the relationship between CA XII expression and tumor malignance, the prognostic significance of CA XII in neoplasms remains controversial. Previous studies showed that CA XII could be considered as a positive prognostic predictor in lung, breast, and cervical cancers [@B5], [@B7], [@B8], whereas others showed that CA XII was a negative prognostic predictor in astrocytoma, glioblastoma, and oral squamous cell carcinoma [@B9]-[@B11]. In the present study, we initially found that the expression of CA XII was related to the pT category and that the expression of CA XII was found in precancerous tissue, which suggested that it was expressed from the early stage of carcinogenesis. Ilie et al. reported that the mRNA and protein levels of CA XII were rapidly down-regulated by a shift to normoxia in non-small cell lung cancer cells, and suggested that cancer cells may require hypoxia-inducible CAXII expression at the early stages of oncogenesis [@B20]. They also indicated that the dynamic CAIX and CAXII response to hypoxia-re-oxygenation promoted aggressive tumor growth. On the other hand, our results showed the expression of CA XII was one of the most important poor prognostic factors in pT2-3 ESCC. Several studies demonstrated that the gene expression of HIF-1 increased at the same time as the overexpression of CA XII, suggesting that CA XII predicts a poor prognosis in circumstances in which the expression of HIF-1 is also elevated [@B21], [@B22]. Although this mechanism needs to be elucidated in more detail in further studies, our results suggest the important and specific roles of CAXII in advanced ESCC.

Regarding results of CA XII immunohistochemistry, some parabasal cells in normal esophageal mucosa seem to show rather nuclear immuno-reactivity as opposed to cancer cells where staining of cell membrane has been identified. Recent reports indicate that CA IX interacts with proteins involved in nuclear/cytoplasmic transport, gene transcription, and protein stability, suggesting the existence of nuclear CA IX protein subpopulations with a potential intracellular function, distinct from the crucial CA IX role at the cell surface [@B23], [@B24]. Although roles of CA XII in nuclear have not been fully investigated, our results suggest that there are some differences of CA XII function between normal epithelial cells and cancer cells.

Recent studies reported that ion channels/transporters play important roles in fundamental cellular functions, and a cellular physiological approach is currently regarded as a promising target for specific cancer treatments [@B25]. We previously investigated the roles of ion transporters [@B26]-[@B30], water channels [@B31], and regulator of intracellular pH [@B32] in esophageal and/or gastric cancer. pH regulators, such as anion exchangers, sodium-hydrogen exchangers, vacuolar H^+^-ATPases, and CAs, have the potential to be key therapeutic targets and the silencing of their expression could provide a new therapeutic strategy in future [@B25]. CA IX and XII are predominantly found in tumor cells and lack (or are present in very limited amount) in normal tissues, and therefore, the potential use of CA inhibitors as antitumor agents opens thus a new important research direction [@B33]. In renal cell carcinoma (RCC), the chimeric monoclonal antibody WX-G250 has been developed for therapeutic purposes. It recognises the CA-IX^MN/G250^ antigen expressed in 95% of clear cell RCC [@B34], [@B35]. The reactivity of WX-G250 with normal tissues is restricted to the gastric epithelium and the biliary ducts in the liver, astrocytes in the brain and to the spinal cord, and WX-G250 therapy in patients with metastatic RCC has already shown that its toxicity is mild [@B34], [@B35]. Whereas the CA IX-specific inhibition is under clinical development for therapeutic and diagnostic application, much less is known about CA XII. However, several specific inhibitors of CA XII have already been developed and studied [@B33], [@B36], [@B37], and, therefore, our results may provide an insight into novel hypoxic targeting therapy for ESCC.

In conclusion, the expression of CAXII in ESCC was revealed for the first time in the present study. We found that its expression was a valuable prognostic factor for patients with advanced ESCC. A deeper understanding of the role of CAXII may lead to its use as a crucial biomarker of tumor progression and/or a new therapeutic target for ESCC.
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![CA XII protein expression in human esophageal squamous cell carcinoma (ESCC). **A:** Immunohistochemical staining of non-cancerous esophageal epithelia with the CA XII antibody. Magnification: ×200. **B:** Immunohistochemical staining of primary human ESCC samples with the CA XII antibody. Magnification: ×200. **C:** Immunohistochemical staining of primary human ESCC samples with the low grade expression of CA XII. Magnification: ×200. **D:** Immunohistochemical staining of primary human ESCC samples with the high grade expression of CA XII. Magnification: ×200.](jcav06p0922g001){#F1}

![**A:** Immunohistochemical staining of human esophageal precancerous tissue with the CA XII antibody. CA XII protein expression was found in esophageal dysplasia. Magnification: ×100. **B:** The comparison between CA XII and HIF-1α protein expressions in human ESCC tissues. Immunohistochemical staining patterns of CA XII *(high)* and HIF-1α *(low)* were similar. Magnification: ×40 *(left)*, ×200 *(right).*](jcav06p0922g002){#F2}

![Survival curve of patients after curative resection for esophageal squamous cell carcinoma (ESCC) according to the expression of CA XII. **A:** All patients were classified into two groups: the low grade expression of CA XII (n=35) and high grade expression of CA XII (n=35). **B:** Patients with pT1 ESCC were classified into two groups: the low grade expression of CA XII (n=11) and high grade expression of CA XII (n=22). **C:** Patients with pT2-3 ESCC were classified into two groups: the low grade expression of CA XII (n=24) and high grade expression of CA XII (n=13). \**p*\<0.05: log-rank test.](jcav06p0922g003){#F3}

###### 

Relationships between the expression of CA XII and clinicopathological features of esophageal cancer.

  Variable                                                             CA XII       *p*-Value   
  ------------------------------- ------------------------------------ ------------ ----------- ---------
                                                                       Low          High        
                                                                       Score\<0.5   Score≥0.5   
                                                                       (n=35)       (n=35)      
  Age                             \<65 years                           20           20          1.000
                                  ≥65 years                            15           15          
  Gender                          Male                                 30           29          1.000
                                  Female                               5            6           
  Location of the primary tumor   Ut-Mt                                24           23          1.000
                                  Lt-Ae                                11           12          
  Histological type               Well/moderately differentiated SCC   22           26          0.440
                                  Poorly differentiated SCC            13           9           
  Tumor size                      \<50 mm                              23           25          0.797
                                  ≥50 mm                               12           10          
  Lymphatic invasion              Negative                             14           19          0.338
                                  Positive                             21           16          
  Venous invasion                 Negative                             17           23          0.227
                                  Positive                             18           12          
  pT                              pT1                                  11           22          0.016\*
                                  pT2-3                                24           13          
  pN                              pN0                                  13           20          0.150
                                  pN1-3                                22           15          
  pStage                          I-II                                 19           26          0.134
                                  III-IV                               16           9           
  Invasive front                  positive                             8            17          0.045\*
                                  negative                             27           18          

Ut: upper thoracic esophagus; Mt: middle thoracic esophagus; Lt: lower thoracic esophagus; Ae: abdominal esophagus; pT: Pathological T stage; pN: pathological N stage; pStage: pathological stage; SCC: squamous cell carcinoma.

\**p*\<0.05: Fisher\'s exact test.

###### 

Relationships between the expression of CA XII and clinicopathological features of pT1 esophageal cancer.

  Variable                                                             CA XII       *p*-Value   
  ------------------------------- ------------------------------------ ------------ ----------- ---------
                                                                       Low          High        
                                                                       Score\<0.5   Score≥0.5   
                                                                       (n=11)       (n=22)      
  Age                             \<65 years                           4            11          1.000
                                  ≥65 years                            7            11          
  Gender                          Male                                 10           19          0.712
                                  Female                               1            3           
  Location of the primary tumor   Ut-Mt                                10           16          1.378
                                  Lt-Ae                                1            6           
  Histological type               Well/moderately differentiated SCC   7            18          0.392
                                  Poorly differentiated SCC            4            4           
  Tumor size                      \<50 mm                              10           19          1.000
                                  ≥50 mm                               1            3           
  Lymphatic invasion              Negative                             6            15          0.471
                                  Positive                             5            7           
  Venous invasion                 Negative                             5            18          0.049\*
                                  Positive                             6            4           
  pN                              pN0                                  7            15          1.000
                                  pN1-3                                4            7           
  pStage                          I-II                                 11           19          0.534
                                  III-IV                               0            3           

Ut: upper thoracic esophagus; Mt: middle thoracic esophagus; Lt: lower thoracic esophagus; Ae: abdominal esophagus; pT: Pathological T stage; pN: pathological N stage; pStage: pathological stage; SCC: squamous cell carcinoma.

\**p*\<0.05: Fisher\'s exact test.

###### 

Relationships between the expression of CA XII and clinicopathological features of pT2-3 esophageal cancer.

  Variable                                                             CA XII       *p*-Value   
  ------------------------------- ------------------------------------ ------------ ----------- -------
                                                                       Low          High        
                                                                       Score\<0.5   Score≥0.5   
                                                                       (n=24)       (n=13)      
  Age                             \<65 years                           16           9           1.000
                                  ≥65 years                            8            4           
  Gender                          Male                                 20           10          0.678
                                  Female                               4            3           
  Location of the primary tumor   Ut-Mt                                14           7           1.000
                                  Lt-Ae                                10           6           
  Histological type               Well/moderately differentiated SCC   15           8           1.000
                                  Poorly differentiated SCC            9            5           
  Tumor size                      \<50 mm                              13           6           0.737
                                  ≥50 mm                               11           7           
  Lymphatic invasion              Negative                             8            4           1.000
                                  Positive                             16           9           
  Venous invasion                 Negative                             12           5           0.731
                                  Positive                             12           8           
  pN                              pN0                                  6            5           0.321
                                  pN1-3                                18           8           
  pStage                          I-II                                 8            7           0.300
                                  III-IV                               16           6           

Ut: upper thoracic esophagus; Mt: middle thoracic esophagus; Lt: lower thoracic esophagus; Ae: abdominal esophagus; pT: Pathological T stage; pN: pathological N stage; pStage: pathological stage; SCC: squamous cell carcinoma.

\**p*\<0.05: Fisher\'s exact test.

###### 

Three-year survival rates of patients with pT2-3 esophageal cancer according to various clinicopathological parameters.

  Variables                                                            3-year survival rate (%)   *p*-Value
  ------------------------------- ------------------------------------ -------------------------- -----------
  Age                             \<65 years                           65.6                       0.658
                                  ≥65 years                            53.5                       
  Gender                          Male                                 55.4                       0.628
                                  Female                               66.7                       
  Location of the primary tumor   Ut-Mt                                69.1                       0.193
                                  Lt-Ae                                42.9                       
  Histological type               Well/moderately differentiated SCC   57.8                       0.845
                                  Poorly differentiated SCC            55.1                       
  Tumor size                      \<50 mm                              61.1                       0.508
                                  ≥50 mm                               53.9                       
  Lymphatic invasion              Negative                             81.8                       0.041\*
                                  Positive                             45.5                       
  Venous invasion                 Negative                             68.4                       0.251
                                  Positive                             47.3                       
  pN                              pN0                                  72.7                       0.184
                                  pN1-3                                49.9                       
  pStage                          I-II                                 71.4                       0.171
                                  III-IV                               47.2                       
  CA XII                          Low (Score\<0.5)                     70.3                       0.011\*
                                  High (Score≥0.5)                     29.1                       

Ut: upper thoracic esophagus; Mt: middle thoracic esophagus; Lt: lower thoracic esophagus; Ae: abdominal esophagus; pT: Pathological T stage; pN: pathological N stage; pStage: pathological stage; SCC: squamous cell carcinoma.

\**p*\<0.05: log-rank test.

###### 

Prognostic factors of pT2-3 esophageal cancer according to a multivariate analysis.

  Variables                               Risk ratio   95% CI         *p*-Value
  -------------------- ------------------ ------------ -------------- -----------
  Lymphatic invasion   Negative           Ref                         
                       Positive           6.983        1.794-47.089   0.003\*
  pN                   pN0                Ref                         
                       pN1-3              5.794        1.571-29.697   0.007\*
  CA XII               Low (Score\<0.5)   Ref                         
                       High (Score≥0.5)   7.977        2.373-30.278   0.001\*

pN: pathological N stage; Ref: referent.

\**p*\<0.05: Cox\'s proportional hazards model; 95% CI: 95% confidence interval.
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